Angela Gueli

Angela Gueli

Auto-generated profile, based on publicly available information

Angela Gueli

Onco-hematology Div., IEO, European Institute of Oncology IRCCS, Milan, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CTCorrado Tarella
Corrado Tarella
Roberto PasseraRoberto Passera
Roberto Passera
MMMichele Magni
Michele Magni
FBFabio Benedetti
Fabio Benedetti
ARAndrea Rossi
Andrea Rossi
ARAlessandro Rambaldi
Alessandro Rambaldi
Purpose: High-dose chemotherapy with peripheral blood progenitor cell (PBPC) autograft is effective in high-risk lymphoma, particularly with the addition of rituximab; however, it is associated with risk of secondary malignancy. These issues have been addressed in a series of 1,347 patients with lymphoma treated with a high-dose sequential (HDS) program. Patients and Methods: A total of 1,024 patients with B-cell lymphoma, 234 patients with Hodgkin's lymphoma, and 89 patients with T-cell lymphoma were treated with HDS between 1985 and 2005 at 11 Gruppo Italiano Terapie Innovative Linfomi centers. HDS was given as salvage treatment to 707 patients (52%); 655 patients (49%) received a modified HDS, with high-dose cytarabine and two consecutive PBPC harvests. Rituximab-supplemented HDS was given to 523 patients (39%). Results: At a median follow-up of 7 years, the median overall survival (OS) was 16.2 years; in B-cell lymphoma the OS was significantly superior with rituximab HDS compared to HDS alone. The cumulative incidence at 5 and 10 years of secondary myelodysplasia/acute leukemia (sMDS/AL) were 3.09% and 4.52%, respectively, that of solid tumors were 2.54% and 6.79%, respectively. Factors associated with sMDS/AL were male sex and use of the second harvest PBPC for the graft; factors found to be associated with solid tumor were advanced age, post-HDS radiotherapy, and rituximab addition to HDS. Despite the increased risk of solid tumors, rituximab addition to HDS was still associated with survival advantages. Conclusion: This analysis has relevant implications for the design and use of intensive chemoimmunotherapy with autograft. In addition, it offers useful insights toward the understanding and prevention of tumor development.

30 September 2013 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ARAlessandro Rambaldi
Alessandro Rambaldi
CBCristina Boschini
Cristina Boschini
GGGiuseppe Gritti
Giuseppe Gritti
FDFederica Delaini
Federica Delaini
EOElena Oldani
Elena Oldani
CTCorrado Tarella
Corrado Tarella

1 March 2016 in Clinical Radiology
Verified
Journal Article
Closed access
ABA. Balbo-Mussetto
A. Balbo-Mussetto
SCS. Cirillo
S. Cirillo
RBR. Bruna
R. Bruna
AGA. Gueli
A. Gueli
CSC. Saviolo
C. Saviolo
CTC. Tarella
C. Tarella

1 June 2013 in Autoimmunity Reviews
Verified
Journal Article
Closed access
CTC. Tarella
C. Tarella
AGA. Gueli
A. Gueli
MRM. Ruella
M. Ruella
ACA. Cignetti
A. Cignetti

25 September 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CTCorrado Tarella
Corrado Tarella
AGAngela Gueli
Angela Gueli
FDFederica Delaini
Federica Delaini
ARAndrea Rossi
Andrea Rossi
ABAnna Maria Barbui
Anna Maria Barbui
ARAlessandro Rambaldi
Alessandro Rambaldi
Primary refractory disease is a main challenge in the management of non-Hodgkin’s Lymphoma (NHL). This survey was performed to define the rate of refractory disease to first-line therapy in B and T-cell NHL subtypes and the long-term survival of primary refractory compared to primary responsive patients. Medical records were reviewed of 3,106 patients who had undergone primary treatment for NHL between 1982 and 2012, at the Hematology Centers of Torino and Bergamo, Italy. Primary treatment included CHOP or CHOP-like regimens (63.2%), intensive therapy with autograft (16.9%), or other therapies (19.9%). Among B-cell NHL, 1,356 (47.8%) received first-line chemotherapy with rituximab. Refractory disease was defined as stable/progressive disease, or transient response with disease progression within six months. Overall, 690 (22.2%) patients showed primary refractory disease, with a higher incidence amongst T-cell compared to B-cell NHL (41.9% vs. 20.5%, respectively, p<0.001). Several other clinico-pathological factors at presentation were variably associated with refractory disease, including histological aggressive disease, unfavorable clinical presentation, Bone Marrow involvement, low lymphocyte/monocyte ration and male gender. Amongst B-cell NHL, the addition of rituximab was associated with a marked reduction of refractory disease (13.6% vs. 26.7% for non-supplemented chemotherapy, p<0.001). Overall, primary responsive patients had a median survival of 19.8 years, compared to 1.3 yr. for refractory patients. A prolonged survival was consistently observed in all primary responsive patients regardless of the histology. The long life expectancy of primary responsive patients was documented in both series managed before and after 2.000. Response to first line therapy resulted by far the most predictive factor for long-term outcome (HR for primary refractory disease: 16.52, p<0.001). Chemosensitivity to primary treatment is crucial for the long-term survival in NHL. This supports the necessity of studies aimed to early identify refractory disease and to develop different treatment strategies for responsive and refractory patients.

5 June 2013 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SFSimone Ferrero
Simone Ferrero
LMLuigia Monitillo
Luigia Monitillo
BMBarbara Mantoan
Barbara Mantoan
DBDaniela Barbero
Daniela Barbero
EGElisa Genuardi
Elisa Genuardi
MLMarco Ladetto
Marco Ladetto